Latest News for TOVX
- Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC - - Combined feedback from FDA and previously from EMA enables company to finalize protocol for pivotal Phase 3 clinical trial while pursuing strategic funding opportunities ROCKVILLE, Md.
- Avances en el desarrollo clínico del VCN-01 para el adenocarcinoma ductal pancreático y el retinoblastoma - - Concesión de la licencia de SYN-020 a Rasayana Therapeutics para su desarrollo en múltiples indicaciones; hasta 38 millones de dólares en posibles hitos, más regalías sobre las ventas comerciales - - Efectivo y equivalentes de efectivo por valor de 13,1 millones de dólares a 31 de diciembre de 2025; las…
Theriva Biologics, Inc. (NYSEAMERICAN:TOVX - Get Free Report)'s stock price traded down 4.9% on Wednesday. The stock traded as low as $0.1926 and last traded at $0.2007. 2,809,196 shares were traded during trading, a decline of 74% from the average session volume of 10,784,255 shares. The stock had previously closed at $0.2110. Theriva Biologics
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TOVX.
U.S. House Trading
No House trades found for TOVX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.